Richard I. Smith is principal, RIS Consulting and a past executive vice president for policy and research of PhRMA.
A few weeks ago, we looked at the Medicare Payment Advisory Commission’s (MedPAC) discussion about drug spending in Medicare and provided some important additional context.
Today and tomorrow in our two-part post, we’ll add further context to the information from MedPAC. We’ll be talking about three topics:
- How has the share of Medicare spending on drugs changed between 2007 and 2013?
- Why is the share of spending on drugs different in Medicare than in the overall National Health Expenditures?
- What is actually included in Medicare spending on drugs?